<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873271</url>
  </required_header>
  <id_info>
    <org_study_id>MDT20033</org_study_id>
    <nct_id>NCT04873271</nct_id>
  </id_info>
  <brief_title>Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study</brief_title>
  <acronym>TITAN 1</acronym>
  <official_title>Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedtronicNeuro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, feasibility study to characterize the procedure for the&#xD;
      implantable TNM device in subjects with overactive bladder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial information was submitted voluntarily under the applicable law and,&#xD;
      therefore, certain submission deadlines may not apply. (That is, clinical trial information&#xD;
      for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public&#xD;
      Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by&#xD;
      sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">August 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the TNM device implant procedure</measure>
    <time_frame>14 days</time_frame>
    <description>This information will be collected through a series of questions for participating investigators via a case report form at implant through the 14-day follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the TNM device initial system use</measure>
    <time_frame>14 days</time_frame>
    <description>This information will be collected through programming and device data at implant through the 14-day follow-up visit.</description>
  </primary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Overactive Bladder</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Implantable Tibial Neuromodulation (TNM) System</intervention_name>
    <description>Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:&#xD;
&#xD;
          1. Subjects 18 years of age or older&#xD;
&#xD;
          2. Have a diagnosis for at least 6 months of OAB&#xD;
&#xD;
          3. No OAB pharmacotherapy for 2 weeks prior to the baseline voiding diary&#xD;
&#xD;
          4. Willing and able to accurately complete study diaries, questionnaires, attend visits,&#xD;
             operate the system and comply with the study protocol&#xD;
&#xD;
          5. Willing and able to provide signed and dated informed consent&#xD;
&#xD;
        Primary Exclusion Criteria:&#xD;
&#xD;
          1. Have neurological conditions such as multiple sclerosis, clinically significant&#xD;
             peripheral neuropathy or spinal cord injury&#xD;
&#xD;
          2. Severe uncontrolled diabetes&#xD;
&#xD;
          3. History of urinary retention within the previous 6 months&#xD;
&#xD;
          4. Current symptomatic urinary tract infection&#xD;
&#xD;
          5. Have primary stress incontinence or mixed incontinence where the stress component&#xD;
             overrides the urge component&#xD;
&#xD;
          6. Current urinary tract mechanical obstruction&#xD;
&#xD;
          7. Have knowledge of planned magnetic resonance imaging (MRIs) or diathermy&#xD;
&#xD;
          8. History of a prior implantable tibial neuromodulation system&#xD;
&#xD;
          9. Skin lesions or compromised skin integrity at the implant site&#xD;
&#xD;
         10. Anatomical defects, clinically significant edema or previous surgeries which precludes&#xD;
             use of the device&#xD;
&#xD;
         11. Previous pelvic floor surgery in the last 6 months&#xD;
&#xD;
         12. Women who are pregnant or planning to become pregnant&#xD;
&#xD;
         13. Characteristics indicating a poor understanding of the study or characteristics that&#xD;
             indicate the subject may have poor compliance with the study protocol requirements.&#xD;
&#xD;
         14. Any subject who is considered to be part of a vulnerable patient population.&#xD;
&#xD;
         15. Concurrent participation in another clinical study that may add additional safety&#xD;
             risks and/or confound study results.** **Subjects in concurrent studies can only be&#xD;
             enrolled with permission from Medtronic.&#xD;
&#xD;
        Contact Medtronic's study manager to determine if the subject can be enrolled in both&#xD;
        studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Miller</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Urology</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Research and Consulting</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FirstHealth Urogynecology</name>
      <address>
        <city>Hamlet</city>
        <state>North Carolina</state>
        <zip>28345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Partners of North Texas</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milwaukee Urogynecology Ascension Medical Group</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

